KEROS THERAPEUTICS INC. - COMMON STOCK

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

14 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

09 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

03 Jan 2024 20:29:25 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Proposed Public Offering of Common Stock

03 Jan 2024 15:05:39 By Nasdaq GlobeNewswire

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

11 Dec 2023 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

06 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

05 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

27 Jul 2023 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

12 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

09 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

22 May 2023 08:00:00 By Nasdaq GlobeNewswire